Cerebral venous sinus thrombosis (CVST) is not significantly linked to COVID-19 vaccines or non-COVID vaccines in a large multi-state US health system

Abstract Cerebral venous sinus thrombosis (CVST) has been reported in a small number of individuals who have received the mRNA vaccines1or the adenoviral vector vaccines for COVID-19 in the US2and Europe3. Continued pharmacovigilance is integral to mitigating the risk of rare adverse events that clinical trials are underpowered to detect, however, these anecdotal reports have led to the pause or withdrawal of some vaccines in many jurisdictions and exacerbated vaccine hesitancy at a critical moment in the fight against the COVID-19 pandemic. We investigated the frequencies of CVST seen among individuals who received FDA-authorized COVID-19 vaccines from Pfizer-BioNTech (n = 94,818 doses), Moderna (n = 36,350 doses) and Johnson & Johnson - J&J (n = 1,745 doses), and among individuals receiving one of 10 FDA-approved non-COVID-19 vaccines (n = 771,805 doses). Comparing the incidence rates of CVST in 30-day time windows before and after vaccination, we found no statistically significant differences for the COVID-19 vaccines or any other vaccines studied in this population. In total, we observed 3 cases of CVST within the 30 days following Pfizer-BioNTech vaccination (2 females, 1 male; Ages (years): [79, 80, 84]), including one individual with a prior history of thrombosis and another individual with recent trauma in the past 30 days. We did not observe any cases of CVST among the patients receiving Moderna or J&J vaccines in this study population. We further found the baseline CVST incidence in the study population between 2017 and 2021 to be 45 to 98 per million patient years. Overall, this real-world evidence-based study highlights that CVST is rare and is not significantly associated with COVID-19 vaccination. In addition, there is a need for a concerted international effort to monitor EHR data across diverse patient populations and to investigate the underlying biological mechanisms leading to these rare clotting events..

Medienart:	Preprint

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	bioRxiv.org - (2022) vom: 25. Dez. Zur Gesamtaufnahme - year:2022

Sprache:	Englisch

Beteiligte Personen:

Pawlowski, Colin [VerfasserIn] Rincón-Hekking, John [VerfasserIn] Awasthi, Samir [VerfasserIn] Pandey, Viral [VerfasserIn] Lenehan, Patrick [VerfasserIn] Venkatakrishnan, AJ [VerfasserIn] Bade, Sairam [VerfasserIn] O’Horo, John C. [VerfasserIn] Virk, Abinash [VerfasserIn] Swift, Melanie D. [VerfasserIn] Williams, Amy W. [VerfasserIn] Gores, Gregory J. [VerfasserIn] Badley, Andrew D. [VerfasserIn] Halamka, John [VerfasserIn] Soundararajan, Venky [VerfasserIn]

Links:	Volltext [lizenzpflichtig] Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.1101/2021.04.20.21255806

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XBI020450508